Abstract: The invention relates to a stable supersaturated aqueous solution comprising bilastine and an selected from glutaric acid, citric acid, ?-cetoglutaric acid, tartaric acid, acetic acid, propionic acid and mixtures thereof and to its use in the treatment and/or prevention of conditions mediated by H1 histamine receptor, such as allergic disorders or diseases. The invention also relates to the use of the above organic carboxylic acids to increase the aqueous solubility of bilastine.

Abstract: The invention relates to a cocrystal comprising a) at least bilastine and, b) at least a cocrystal forming compound selected from the group consisting of glutaric acid, adipic acid, sorbic acid, succinic acid, benzoic acid, 4-aminobenzoic acid, L-malic acid, resorcinol, methyl 4-hydroxy benzoate and N-(4-hydroxyphenyl)acetamide and mixtures thereof, or a solvate thereof. The invention further relates to methods for obtaining said cocrystals and to their use in the treatment and/or prevention of conditions mediated by H1 histamine receptor, such as allergic disorders or diseases. The invention also relates to a method for increase the aqueous solubility of the above compounds of formula (I).

Abstract: The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, a method of synthesis of said compounds, pharmaceutical compositions comprising them and their use in the treatment and/or prevention of conditions mediated by H1 histamine receptor, such as allergic disorders or diseases.

Abstract: The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, a method of synthesis of said compounds, pharmaceutical compositions comprising them and their use in the treatment and/or prevention of conditions mediated by H1 histamine receptor, such as allergic disorders or diseases.

Abstract: A compound of formula (I): or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, and a method for the treatment of an acute or chronic inflammatory disease by inhibiting the production of at least one pro-inflammatory cytokine selected from TNF-alpha, IFN-gamma, IL-8 and IL-10, involving administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (I) as defined above.

Abstract: A compound of formula (I): or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, and a method for the treatment of an acute or chronic inflammatory disease by inhibiting the production of at least one pro-inflammatory cytokine selected from TNF-alpha, IFN-gamma, IL-8 and IL-10, involving administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (I) as defined above.

Abstract: The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, and to a method for the treatment an acute or chronic inflammatory disease by inhibiting the production of at least one pro-inflammatory cytokine selected from TNF-alpha, IFN-gamma, IL-8 and IL-10, which comprises administering to a patient who needs such treatment a therapeutically effective amount of a compound of formula (I) as defined above.

Abstract: Crystalline form 1 4-[2-[4-[1 -(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]-ethyl]-??-dimethyl-benzeneacetic acid of formula (I) is described, procedures for its preparation, pharmaceutical formulae containing crystalline form 1 and the use of crystalline form 1 to treat allergic reactions and pathological processes mediated by histamine in mammals such as man.

Abstract: The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, and to a method for the treatment an acute or chronic inflammatory disease by inhibiting the production of at least one pro-inflammatory cytokine selected from TNF-alpha, IFN-gamma, IL-8 and IL-10, which comprises administering to a patient who needs such treatment a therapeutically effective amount of a compound of formula (I) as defined above.

Abstract: Crystalline form 1 of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1 -piperidinyl]ethyl]-??-dimethyl-benzen?eacetic acid Crystalline form 1 of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1 -piperidinyl]ethyl]-??-dimethyl-benzen?eacetic acid of formula (I) is described, procedures for its preparation, pharmaceutical formulae containing crystalline form 1 and the use of crystalline form 1 to treat allergic reactions and pathological processes mediated by histamine in mammals such as man.

Abstract: Polymorph 1 of 4-[2-[1-(2-ethoxyethyl)-1H-benzidimazole-2-yl]-1-piperidinyl]ethyl]-??-dimethyl-benzenoacetic acid of formula (I) is described, procedures for its preparation, pharmaceutical formulae containing polymorph 1 and the use of polymorph 1 to treat allergic reactions and pathological processes mediated by histamine in mammals such as man.

Abstract: Thaumatins, protein sweeteners, are obtained through the expression of artificial, synthetic and substantially optimized genes, preferably in filamentous fungi such as Penicillium roquefortii, Aspergillus niger and Aspergillus niger var. awamori. Preparing substantially optimized artificial genes allows for high protein expression, making the process useful for industrial production of this valuable sweetener. Thaumatins may be obtained extracellularly and intracellularly. Intracellular production provides thaumatin-containing fungi that can be used per se in animal feed without prior separation of the fungal mycelium.

Abstract: New benzimidazole derivatives of formula: ##STR1## in which R.sub.1 is H or a short chain hydrocarbon group such as methyl, hyl, isopropyl, cyclopropyl, vinyl, etc., and R.sub.2 is a group selected from among the following: CH.sub.2 OH, COOH, COOR.sub.3 and 4,4-dimethyl-2-oxazolinyl, R.sub.3 being a short chain alkyl group such as methyl, ethyl, etc., are described.A description is also made of the preparation of these compounds, which have a high H.sub.1 antihistaminic and antiallergic activity and are devoid of effects on the central nervous and cardiovascular systems.

Abstract: New piperidine derivatives of benzimidazole of the formula: ##STR1## wherein n is 1 or 2 and R is lower alkyl, lower alkenyl or lower cycloal, or a pharmaceutically acceptable salt thereof, are useful antihistaminic and antiallergic agents.

Abstract: A description is made of the preparation of new 2-piperazinylbenzimidazole erivatives, of general formula ##STR1## where R can be a hydrogen atom, a short chain alkyl group and a phenyl radical, substituted in position four by a halogen, and R.sub.1 can be a hydrogen atom, an alkoxycarbonyl radical, a hydroxymethyl group and a diphenylmethyl group, and their addition salts with pharmaceutically acceptable acids.These compounds are pharmacologically active as antagonists of the serotonin 5HT.sub.3 receptors.

Abstract: The provision of Cephalosporium acremonium resistant to the aminoglycoside G418 allows the use of this aminoglycoside as a marker to select aminogylcoside-resistant cells of Cephalosporium acremonium from non-resistant cells of Cephalosporium acremonium. Aminoglycoside resistance can be imparted by transformation of Cephalosporium acremonium with a suitable vector.